We are live on ! Find out more
NEUP

Neuphoria Therapeutics
NEUP

4 hedge funds and large institutions have $1.62M invested in Neuphoria Therapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

11% more capital invested

Capital invested by funds: $1.46M → $1.62M (+$160K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$926K
2
UBS Group
UBS Group
Switzerland
+$5.38K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$7.55K
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
1
Woodline Partners
California
$651K -$7.55K -87 -0.7%
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$595K +$926K +10,667 New
BI
3
BVF Inc
California
$373K – – –
UBS Group
4
UBS Group
Switzerland
$4.05K +$5.38K +62 +564%

NEUP Hedge Fund Activity: Q4 2022 in Review

4 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q4 2022, worth a combined $1.62M — up 11% from $1.46M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NEUP positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $926K. The largest seller was Woodline Partners, cutting an estimated $7.55K.

  • 4 institutional investors held Neuphoria Therapeutics (NEUP) as of Q4 2022, up from 3 in Q3 2022.
  • Funds reported $1.62M of Neuphoria Therapeutics stock for Q4 2022, up 11% quarter-over-quarter.
  • 1 fund opened new Neuphoria Therapeutics positions in Q4 2022 and 0 closed out, a net change of +1 holder.
  • The largest Neuphoria Therapeutics buyer in Q4 2022 was Point72 Asset Management, an estimated $926K added.
  • The largest Neuphoria Therapeutics seller in Q4 2022 was Woodline Partners, an estimated $7.55K sold.

Based on aggregated 13F filings for Q4 2022.